CELL & GENE THERAPY INSIGHTS

Viral vector bioprocessing

Guest Editor:
Anindya Dasgupta, Director, Vector Development at Expression Therapeutics
Anindya Dasgupta
Director, Vector Development at Expression Therapeutics
Anindya is the director of vector development at Expression Therapeutics. He obtained his PhD from University of South Carolina. His post-doctoral training and research associateship at the school of medicine, Emory University, Atlanta were focussed on the evaluation of novel anti-cancer therapies and the development of strategies for expansion and lentivirus based bioengineering of  T cells in serum free media . Anindya is a co-inventor of a patent on anti-cancer strategy. He was also the Director of Laboratory at KIYATEC Inc. At his recent role at Cincinnati Children’s Hospital Medical Centre he led vector development to manufacture high titer lentiviral vectors.

Current and future perspectives on lentiviral vector bioprocess...

P Carter
Paul Carter
Head of Vector Processing at Quell Therapeutics
Paul Carter is the Head of Vector Processing at Quell Therapeutics Limited and has over 30 years’ experience in the pharmaceutical industry, working across cell and gene therapy, biopharmaceutical and small molecule R&D. Prior to joining Quell, he was leading GSK’s Downstream Process Development Group in Cell and Gene Therapy.
4 May 2021
Interview

Gammaretroviral and lentiviral vector manufacture: brief...

R Sengupta
Ranjita Sengupta
Adicet Bio, 200 Constitution Drive, Menlo Park, CA-94025, USA
29 April 2021
Expert Insight

Yesterday, today and tomorrow: the evolving landscape of...

D Knop
David R Knop, PhD
Vice President of Process Development, AGTC
29 April 2021
Commentary

Making the move from antibody therapeutics to gene therapy:...

A Tustian
Andrew D Tustian
Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA andrew.tustian@regeneron.com
29 April 2021
Commentary

Facilitating gene therapy development with solutions to...

S Darling
Susan Darling
Senior Director Product Management, Market Management, CE and Biopharma, SCIEX
29 April 2021
Innovator Insight

Simplifying AAV protein analytics with Maurice

C Heger
Chris Heger PhD
Director, Applications Science
Chris Heger, Senior Manager of Applications Science for the Analytical Solutions Division of Bio-Techne, leads a team chartered with creating scientific collateral, fostering collaborations, training, and coming up with new applications. Chris has expertise in immunoassays, capillary electrophoresis, antibody design and production, and chromatography. In recent years, his team has focused on developing analytical solutions for cell and gene therapy researchers.Chris received his doctoral degree in Pharmacology from Cornell University and completed his post-doctoral training at the National Cancer Institute. Working in the Antibody and Protein Purification Unit, Chris oversaw antibody development projects, from immunogen design to final product. A unique aspect of his postdoctoral training was his role in the evaluation of new technologies, serving as the gateway for cutting edge instrumentation to get into use at the NCI/NIH. Through this role, Chris became well-acquainted with ProteinSimple and after completing his postdoctoral training, began working for ProteinSimple (now part of Bio-Techne).
29 April 2021
FastFacts
  • Improving upon legacy vector and plasmid bioprocess technology for tomorrow’s...

    M Lundgren,
    P Guterstam,
    H Ihre
    Mats Lundgren
    Mats Lundgren
    Customer Applications Director at Cytiva
    Peter Guterstam
    Peter Guterstam
    Product Manager, Advanced Therapeutics Downstream Solutions at Cytiva
    Henrik Ihre
    Henrik Ihre
    Director Strategic Technologies at Cytiva
    18 May 2021
    1
    Days
    5
    Hrs
    46
    Min
    Register
  • Protein biomarkers in plasma: revealing biological insights into the...

    G Boland,
    A Mehta
    Genevieve  Boland
    Genevieve Boland
    Surgical Oncologist at Massachusetts General Hospital
    Arnav  Mehta
    Arnav Mehta
    Postdoctoral Researcher at Broad Institute of MIT and Harvard
    20 May 2021
    3
    Days
    5
    Hrs
    46
    Min
    Register
  • Overcoming purification challenges in antibody therapeutics manufacturing...

    L Sierkstra
    Laurens  Sierkstra
    Laurens Sierkstra
    Business Leader at Thermo Fisher Scientific
    10 Jun 2021
    24
    Days
    5
    Hrs
    46
    Min
    Register
  • Strategies to advance the donor selection process for cell therapies...

    M Maiers,
    E Petersdorf,
    K Wadsworth et al.
    Martin Maiers
    Martin Maiers
    Vice President, Innovation at Be The Match BioTherapies
    Effie Wang Petersdorf
    Effie Wang Petersdorf
    Managing Director, Clinical Research Division at Fred Hutchinson Cancer Research Center
    Kim Wadsworth
    Kim Wadsworth
    Senior Immunogenetic Specialist at Be The Match BioTherapies
    Ray Sajulga
    Ray Sajulga
    Bioinformatics Scientist at Be The Match BioTherapies
    17 Jun 2021
    31
    Days
    5
    Hrs
    46
    Min
    Register
  • Key considerations for maximizing LV and AAV production in transient...

    L Kopp,
    B Larimore
    Leisha Kopp
    Leisha Kopp
    Technical Applications Scientist at Mirus Bio LLC
    Beth Larimore
    Beth Larimore
    Associate Director of Viral Vector Process Development at Bristol Myers Squibb
    9 Jun 2021
    23
    Days
    5
    Hrs
    46
    Min
    Register
  • Navigating regulations - novel cell therapy platforms and their path...

    N Bauer,
    N Calhoun,
    A Davies et al.
    Nina Bauer
    Nina Bauer
    Head, Commercial, Gene Editing & Novel Modalities at MilliporeSigma
    Natika Calhoun
    Natika Calhoun
    Director, Quality Assurance, Viral & Gene Therapy at MilliporeSigma
    Anthony Davies
    Anthony Davies
    President at Dark Horse Consulting, Inc.
    Matt Muldoon
    Matt Muldoon
    Senior Director, Sourcing & Supplier Management at Allogene Therapeutics, Inc
    27 May 2021
    10
    Days
    5
    Hrs
    46
    Min
    Register
  • Key lessons for cell & gene therapy and mRNA therapeutic development from COVID-19...

    S Zobbi,
    V Indurthi,
    C Kröner et al.
    Scott Zobbi
    Scott Zobbi
    Senior Business Development Manager, Custom POROS Chromatography Resins. at Thermo Fisher Scientific
    Venkata  Indurthi
    Venkata Indurthi
    Director, Research & Development at Aldevron LLC
    Christoph Kröner
    Christoph Kröner
    Director DNA Process Development & Cap Technology at BioNTech IMFS
    Joseph Barberio
    Joseph Barberio
    Director, Process Development at Strand Therapeutics Inc.
    22 April 2021
    Watch now
  • Applying Warp Speed lessons to your ATMP manufacturing facility

    J Bornholdt,
    C Heffernan,
    T Page et al.
    James Bornholdt
    James Bornholdt
    Architect at CRB
    Charles Heffernan
    Charles Heffernan
    Director at CRB
    Thomas Page
    Thomas Page
    Vice President - Engineering & Asset Development at Fujifilm Diosynth Biotechnologies
    Jarrod Wrampe
    Jarrod Wrampe
    Process Utility Engineer at CRB
    12 May 2021
    Watch now
  • From first collection to commercial launch: Streamlining your supply chain...

    C McClain,
    A Baquiran
    Chris McClain
    Chris McClain
    Head of Business Development & Sales at Be The Match BioTherapies
    Aileen Baquiran
    Aileen Baquiran
    Senior Director, Business Operations
    6 May 2021
    Watch now
  • Key considerations for hMSC product and process development through clinical...

    J Rowley,
    R Bárcia,
    J Candiello et al.
    Jon Rowley
    Jon Rowley
    Founder & Chief Technology Officer at RoosterBio Inc
    Rita Nogueira Bárcia
    Rita Nogueira Bárcia
    Vice President, R&D
    Joseph Candiello
    Joseph Candiello
    Product Manager at RoosterBio Inc
    Joseph Takacs
    Joseph Takacs
    at RoosterBio Inc
    Jan Nolta
    Jan Nolta
    Director - Stem Cell Program Sacramento at University of California Davis
    Carolyn Yeago
    Carolyn Yeago
    Associate Director at Georgia Institute of Technology
    Jim Birkhead
    Jim Birkhead
    Director, Research & Development at Vericel Corporation
    28 April 2021
    Watch now
  • Ultrahigh-content imaging helps to identify CAR target candidates against pancreatic...

    D Schäfer
    Daniel Schäfer
    Daniel Schäfer
    Team Coordinator R&D at Miltenyi Biotec
    20 April 2021
    Watch now
  • Scalable suspension LVV production platforms for cell and gene therapy

    S Sanyal,
    M Haller,
    Y Shin
    Suparna Sanyal
    Suparna Sanyal
    Head of Viral Vectors Commercial Development, Lonza Pharma & Biotec
    Michael Haller
    Michael Haller
    Senior R&D Scientist, Viral Vector Process Development, Lonza Pharma & Biotec
    Young Shin
    Young Shin
    R&D Principal Scientist, Cell & Gene Technologies, Lonza Pharma & Biotec
    13 April 2021
    Watch now
  • Channel content

    Reports

    FEATURING

    Current status and future perspective of gene therapy products in Japan

    Y Maruyama,
    Yoshiaki Maruyama
    Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency
    A Sakurai,
    Akira Sakurai
    Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency
    M Kasai et al.
    Masaki Kasai
    Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency

    Examining Health Canada’s agile new approach to regulating Advanced Therapeutic Products

    E Toller,
    Elizabeth Toller
    Executive Director, Regulatory Innovation (Health Products and Food Branch), Health Canada
    L Gillham-Eisen,
    Liz Anne Gillham-Eisen
    Director of the Office of Policy and International Collaboration, Health Canada
    N Kolas
    Nadine Kolas
    Senior Policy Analyst, Office of Policy and International Collaboration, Health Canada

    FEATURING

    2021: a key year for allogeneic cellular cancer immunotherapy?

    S Kili
    Sven Kili
    Principal at Sven Kili Consulting
    Sven Kili provides specialist strategic consulting services to innovative Regenerative Medicine companies. His clients include small and medium sized companies from company formation through to clinical development and commercialisation. He was previously the Head of Development for the Cell and Gene Therapy division of GSK Rare Diseases where he led teams developing ex-vivo Gene Therapies for a variety of rare genetic disorders including Strimvelis®, the first ex-vivo gene therapy to be approved for children with ADA-SCID; Wiskott – Aldrich syndrome (WAS); Metachromatic Leukodystrophy (MLD) and Beta-Thalassemia. Prior to this, he was Senior Director, Cell Therapy and Regenerative Medicine for Sanofi (Genzyme) Biosurgery where he led the clinical development, approval and commercialisation activities of the first combined ATMP approval in the EU for MACI®. His team also prepared and submitted Advanced Therapy regulatory filings for Australia and the US, including health technology assessments and he was responsible for late stage developments for Carticel® and Epicel® in the US. Before joining Genzyme, Sven led the cell therapy activities and oversaw all UK & Irish regulatory functions and was the QPPV for pharmacovigilance for the Geistlich Pharma. Sven trained as an Orthopaedic surgeon in the UK and South Africa and since leaving full-time clinical practise has developed expertise Cell and Gene Therapy in clinical development, regulatory compliance, value creation, risk management and product safety, product launches and post-marketing activities. He sits on the board of CCRM in Canada; Xintela – a Swedish Stem Cell company and is the chair of the CGTAC as part of the UK BIA and the VP of the Standards Co-ordinating Body for Regenerative Medicine. Additionally, he still maintains his clinical skills in the UK NHS and serves as an ATLS Instructor in his spare time.

    FEATURING

    Stem cell therapy: current obstacles and innovations

    J Hare
    Joshua Hare
    Chief Sciences Officer, Senior Associate Dean for Experimental and Cellular Therapeutics, Director of the Interdisciplinary Stem Cell Institute (ISCI) and Louis Lemberg Professor of Medicine at the University of Miami Miller School of Medicine

    On my bookshelf...

    Q Rafiq
    Qasim Rafiq
    In CGTI Shelfies, we ask experts within cell and gene therapy to pick the publications that helped shape their field, and their own careers. This week, we take a look into the bookshelf of Qasim Rafiq, Associate Professor in Cell and Gene Therapy Bioprocess Engineering at University College London.
    Associate professor at UCL’s Advanced Centre for Biochemical Engineering, Qasim’s research focus is on addressing translational challenges of robust manufacture of stem cells that are needed to take regenerative medicines into the clinic. This includes the “whole bioprocess” from sourcing of raw materials and cells, through cell expansion in bioreactors and ultimately the downstream processing needed to purify and concentrate cell product for delivery to the patient. He previously lectured in Bioprocess Engineering at Aston University, where he was Principal Investigator on 4 grants with funding from RCUK, EU Horizon 2020, InnovateUK and commercial sources. Qasim completed his PhD at Loughborough.

    On my bookshelf...

    R Deans
    Robert Deans
    CSO at Synthego Corporation

    FEATURING

    Business Insight: cell & gene therapy

    J Mulryne,
    Jackie Mulryne
    Partner, Arnold & Porter
    Jackie Mulryne is a Partner at Arnold & Porter, focusing on regulatory and contentious matters for life sciences companies. She has advised a range of clients on the development and launch of innovative products, and assisted with navigating the regulatory landscape for novel cell and gene therapy products.
    B San Martin,
    Dr Beatriz San Martin
    Partner, Arnold & Porter
    Beatriz San Martin is an intellectual property specialist focusing her practice on the life sciences sector and emerging/disruptive technologies. She has significant experience handling cases before the UK Courts and the Court of Justice of the European Union, including high-profile European litigation. Beatriz was formerly a scientist with a Wellcome Trust PhD and a postdoctoral from the University of Cambridge specializing in genetics, cellular, and molecular biology. She is a member of the UK BioIndustry Association Cell and Gene Therapy Advisory Committee and Engineering Biology Advisory Committee.
    J Schmidt et al.
    John Schmidt
    Partner, Arnold & Porter

    FEATURING

    Boldly de-risking development of impactful cell and gene therapies: the California Stem Cell Agency’s $3B funding model

    S Patel,
    Shyam Patel
    Associate Director, Portfolio Development & Review at California Institute For Regenerative Medicine
    S Talib,
    Sohel Talib
    Director, Therapeutics at California Institute For Regenerative Medicine
    M Millan
    Maria Millan
    Vice President, Therapeutics at California Institute For Regenerative Medicine

    Driving disruptive innovation in the ATMP field

    K Papenfuss
    Kerstin Papenfuss
    Associate Director, Therapeutics at Deep Science Ventures
    Kerstin Papenfuss started her PhD at German Cancer Research Centre and then moved to a lab at Imperial College London to work on novel treatment options within the field of tumor immunology. After a Post Doc in academic drug discovery, she since has spent almost ten years in leadership roles at impact-driven organizations advancing medicine and therapeutics, while also securing an executive MBA and a Women in Business award. Before joining DSV to develop science companies designing more effective therapies, Kerstin was transforming ideas for cutting edge cell and gene therapies into investable propositions at UK’s Cell and Gene Therapy Catapult.

    Latest content

    Overcoming purification challenges in antibody therapeutics manufacturing...

    L Sierkstra
    Laurens Sierkstra
    Laurens Sierkstra
    Business Leader, ThermoFisher Scientific
    10 Jun 2021
    24
    Days
    5
    Hrs
    46
    Min
    Register

    Protein biomarkers in plasma: revealing biological insights into the...

    G Boland,
    A Mehta
    Dr Genevieve Boland
    Dr Genevieve Boland
    Surgical Oncologist, Massachusetts General Hospital
    Dr Arnav Mehta
    Dr Arnav Mehta
    Postdoctoral Researcher, Broad Institute of MIT and Harvard
    20 May 2021
    3
    Days
    5
    Hrs
    46
    Min
    Register

    Improving upon legacy vector and plasmid bioprocess technology for tomorrow’s...

    M Lundgren,
    P Guterstam,
    H Ihre
    Mats Lundgren
    Mats Lundgren
    Customer Applications Director, Life Sciences, Cytiva
    Peter Guterstam
    Peter Guterstam
    Product Manager, Next Generation Resins & Technologies, Cytiva
    Henrik Ihre
    Henrik Ihre
    Director Strategic Technologies, Cytiva
    18 May 2021
    1
    Days
    5
    Hrs
    46
    Min
    Register

    Key lessons for cell & gene therapy and mRNA therapeutic development from COVID-19...

    S Zobbi,
    V Indurthi,
    C Kröner et al.
    Scott Zobbi
    Scott Zobbi
    Senior Business Development Manager, Custom POROS Chromatography Resins, ThermoFisher Scientific
    Venkata Indurthi, PhD
    Venkata Indurthi, PhD
    Vice President, Research and Development, Aldevron
    Christoph Kröner
    Christoph Kröner
    Director DNA Process Development & Cap Technology, BioNTech SE
    Joseph Barberio
    Joseph Barberio
    Director, Process Development at Strand Therapeutics Inc.
    22 April 2021
    Watch now